Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy 
Background
Tumor antigen-specific CD4 + T cells generally orchestrate and regulate innate and adaptive immune cells to provide immune surveillance against malignancy. However, activation of antigen-specific CD4 + T cells is restricted at local tumor sites where antigen-presenting cells are frequently dysfunctional, which can cause rapid exhaustion of anti-tumor immune responses. Herein, we characterize anti-tumor effects of a unique human CD4 + helper T cell subset that directly recognizes the cytoplasmic tumor antigen, NY-ESO-1, presented by MHC class II (MHC-II) on cancer cells. In addition, we clone the TCR gene from tumor-recognizing CD4 + T cells (TR-CD4) and test the function of TCR gene-engineered cells.
Methods NY-ESO-1-specfic CD4 + or CD8 + T cells were obtained from ovarian cancer patients who received NY-ESO-1 vaccine. Full-length TCR α and β chain genes of TR-CD4 were cloned by 5' RACE PCR. TCR gene was transduced into activated T cells by MSCV-based retroviral vector. The effector function was evaluated against cognate peptide-pulsed target cells or NY-ESO-1 + MHC-II + cancer cell lines by ELISA, intracellular cytokine staining or CTL assay.
Results

TR-CD4, but not conventional NY-ESO-1-specific CD4 + T cells, directly recognized cancer cells in MHC-IIdependent and NY-ESO-1-specific manners. Presentation
of intracellular NY-ESO-1 on MHC-II by cancer cells required non-classical MHC-II antigen presentation mechanisms. Upon direct recognition of cancer cells, TR-CD4 potently induced IFN-γ-dependent growth arrest in cancer cells. In addition, direct recognition of cancer cells triggers TR-CD4 to provide help to NY-ESO-1-specific CD8 + T cells by enhancing cytotoxic activity, and improving viability and proliferation. Notably, the TR-CD4 either alone or in combination with NY-ESO-1-specific CD8 + T cells significantly inhibited tumor growth in vivo in a xenograft model. Finally, retroviral gene-engineering of polyclonally activated T cells with TCR derived from TR-CD4 successfully produced large numbers of functional TR-CD4.
Conclusions
These observations provide mechanistic insights into the role of TR-CD4 in tumor immunity, and suggest that approaches to utilize TR-CD4 will augment anti-tumor immune responses for durable therapeutic efficacy in cancer patients. Large numbers of TR-CD4 that directly recognize cancer cells and enhance CD8 + T cell functions can be generated by gene-engineering with TCR from TR-CD4. Antigen-presenting cell-independent provision of CD4-help by TR-CD4 is especially important to enhance durable CD8 + T cell anti-tumor functions at the tumor local site. Adoptive T cell therapy using TR-CD4 in combination with CD8 + T cells could be a promising strategy for effective eradication of tumors.
